s:**
- GPR32 knockout in microglia should worsen neuroinflammation if this is the primary mechanism
- Dose-response studies showing therapeutic window
Background and Rationale
This falsification study rigorously tests the hypothesis that GPR32 serves as a protective receptor in microglial-mediated neuroinflammation by examining the consequences of receptor loss in controlled cellular models. The experiment employs CRISPR-Cas9 gene editing to generate GPR32 knockout BV2 microglia cell lines, which will be challenged with various pro-inflammatory stimuli including lipopolysaccharide, amyloid-β oligomers, and α-synuclein fibrils to assess inflammatory responses. The study design includes comprehensive dose-response analyses to establish therapeutic windows and determine whether GPR32 activation provides concentration-dependent neuroprotection. Inflammatory readouts encompass cytokine profiling (IL-1β, TNF-α, IL-6), nitric oxide production, phagocytic capacity, and transcriptomic analysis to capture global changes in microglial activation states. The falsification approach specifically tests whether GPR32 knockout exacerbates neuroinflammatory responses, as predicted by the protective hypothesis, while also examining potential compensatory mechanisms through related G-protein coupled receptors. Control experiments include rescue studies with GPR32 re-expression and pharmacological modulation with selective agonists and antagonists. This systematic approach will definitively establish whether GPR32 represents a viable therapeutic target for neuroinflammation-related neurodegeneration.
This experiment directly tests predictions arising from the following hypotheses:
- Microglial Efferocytosis Enhancement via GPR32 Superagonists
- Microglial Purinergic Reprogramming
- Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators
- Purinergic P2Y12 Inverse Agonist Therapy
- Purinergic Signaling Polarization Control
Experimental Protocol
Phase 1: Cell Line Preparation and Genetic Modification (Days 1-14)• Generate GPR32 knockout BV2 microglial cell lines using CRISPR-Cas9 system with dual guide RNAs targeting exons 2 and 3
• Validate knockout efficiency by Western blot, qPCR, and sequencing (n=3 independent clones)
• Maintain wild-type BV2 controls and establish stable cell cultures in DMEM + 10% FBS
• Prepare immortalized human microglial cell line (HMC3) as secondary validation model
Phase 2: Neuroinflammation Induction Protocol (Days 15-16)
• Treat cells with LPS (0.1, 1.0, 10 μg/mL) + IFN-γ (20 ng/mL) for 24h to induce neuroinflammation
• Include ATP (5 mM, 30 min) treatment for NLRP3 inflammasome activation
• Establish co-culture system with primary neurons (DIV 7-10) to assess neuronal damage
• Include vehicle controls and unstimulated baseline conditions
Phase 3: Dose-Response Analysis (Days 17-21)
• Test GPR32 agonist RvD1 at concentrations: 0.1, 1, 10, 100 nM, 1 μM over 4h and 24h timepoints
• Assess receptor desensitization by pre-treatment with 100 nM RvD1 for 2h followed by washout and re-stimulation
• Monitor cAMP levels using ELISA at 15 min, 1h, 4h post-treatment to confirm receptor functionality
• Include TREM2 agonist (AL002c, 10 μg/mL) as positive control for phagocytosis enhancement
Phase 4: Functional Readouts and Validation (Days 22-28)
• Measure pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and anti-inflammatory markers (IL-10, TGF-β) by ELISA and qPCR
• Assess phagocytosis capacity using fluorescent Aβ1-42 oligomers (1 μM) and pHrodo-labeled E.coli particles
• Evaluate microglial morphology and activation state using immunofluorescence (Iba1, CD68, TMEM119)
• Perform live-cell imaging for real-time phagocytosis dynamics over 4h periods
Expected Outcomes
GPR32 knockout microglia will show 2-3 fold increased pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) compared to wild-type controls under LPS stimulation, with p<0.01 significance.
Dose-response curve for RvD1 will demonstrate EC50 values between 1-10 nM for anti-inflammatory effects in wild-type cells, with no therapeutic effect in GPR32 knockout cells at any concentration tested.
GPR32 knockout will show 40-60% reduced phagocytosis efficiency for Aβ oligomers and bacterial particles compared to controls, measured by fluorescence intensity and particle uptake quantification.
TREM2 agonist treatment will rescue phagocytosis deficits in GPR32 knockout cells to within 20% of wild-type levels, demonstrating pathway independence.
Receptor desensitization studies will show <15% reduction in cAMP response after RvD1 pre-treatment in the 1-10 nM range, indicating preserved receptor sensitivity in therapeutic window.
Co-culture experiments will demonstrate 25-40% increased neuronal cell death (measured by LDH release and live/dead staining) when neurons are exposed to GPR32 knockout microglial conditioned medium.Success Criteria
•
Statistical significance threshold: All primary endpoints must achieve p<0.05 with Bonferroni correction for multiple comparisons, minimum n=6 per group across 3 independent experiments
• Effect size requirements: GPR32 knockout must show ≥2-fold increase in inflammatory markers and ≥30% reduction in phagocytosis compared to controls (Cohen's d ≥0.8)
• Dose-response validation: Clear sigmoidal dose-response curve with R² ≥0.85 for RvD1 effects in wild-type cells, with complete absence of response in knockout cells
• Knockout validation criteria: ≥95% reduction in GPR32 protein expression by Western blot, confirmed in minimum 3 independent clones with off-target analysis
• Rescue experiment success: TREM2 agonist must restore phagocytosis to ≥80% of wild-type levels in knockout cells, demonstrating pathway specificity
• Reproducibility standard: Primary findings must be replicated in both BV2 and HMC3 cell systems with consistent directional effects and statistical significance